Tarsus Pharmaceuticals (TARS) Equity Ratio: 2020-2025
Historic Equity Ratio for Tarsus Pharmaceuticals (TARS) over the last 5 years, with Sep 2025 value amounting to 0.63.
- Tarsus Pharmaceuticals' Equity Ratio fell 0.68% to 0.63 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.63, marking a year-over-year decrease of 0.68%. This contributed to the annual value of 0.60 for FY2024, which is 19.73% down from last year.
- According to the latest figures from Q3 2025, Tarsus Pharmaceuticals' Equity Ratio is 0.63, which was down 6.71% from 0.67 recorded in Q2 2025.
- Tarsus Pharmaceuticals' Equity Ratio's 5-year high stood at 0.95 during Q2 2021, with a 5-year trough of 0.60 in Q4 2024.
- In the last 3 years, Tarsus Pharmaceuticals' Equity Ratio had a median value of 0.68 in 2025 and averaged 0.71.
- As far as peak fluctuations go, Tarsus Pharmaceuticals' Equity Ratio spiked by 586.45% in 2021, and later decreased by 20.74% in 2024.
- Tarsus Pharmaceuticals' Equity Ratio (Quarterly) stood at 0.93 in 2021, then declined by 9.16% to 0.85 in 2022, then dropped by 12.35% to 0.74 in 2023, then fell by 19.73% to 0.60 in 2024, then fell by 0.68% to 0.63 in 2025.
- Its Equity Ratio stands at 0.63 for Q3 2025, versus 0.67 for Q2 2025 and 0.68 for Q1 2025.